In June 2025, the Advisory Committee on Immunization Practices (ACIP) met under new leadership to discuss the safety and effectiveness of a new monoclonal antibody, Clesrovimab, intended for routine use in healthy newborns. This meeting raised significant public expectations regarding the thorough examination of safety data before recommendations are made.
1. Recommendation for Clesrovimab
• The ACIP voted 5 to 2 to recommend Clesrovimab from Merck, despite its structural similarities to an already approved product, nirsevimab from Sanofi-AstraZeneca.
• The CDC's presentation was deemed reassuring, which influenced the committee's vote.
2. Concerns Over Safety Data Presentation
• The CDC presented safety data focusing on seizures without providing a combined risk analysis across age groups.
• Seizure risks appeared elevated when combined but were labeled as "not significant" due to being split into two groups, leading to a loss of statistical relevance.
3. Mortality Data Omission
• The ACIP was not shown mortality data across the clinical trials for either monoclonal antibody.
• nirsevimab trials revealed an imbalance in deaths favoring the treatment groups, and similar trends were seen in trials for Clesrovimab.
• The total deaths were notably higher in treatment arms, though they went unexamined for causality by the ACIP.
4. Selecting Data for Representation
• Deaths occurring outside the designated follow-up periods were included in reports in a way that misled the understanding of causality.
• Detailed breakdowns of death causes were omitted, which are essential for transparent analysis.
5. Surveillance and Reporting Gaps
• The CDC's safety analysis relied only on one database, the Vaccine Safety Datalink, neglecting other reporting sources like VAERS, which could provide additional safety signals.
• Real-world data from France showed concerning patterns of increased mortality following the rollout of nirsevimab, which were not considered in the ACIP’s decision-making process.
6. Built-In Reporting Blind Spots
• RSV monoclonal antibodies are classified with childhood vaccines for legal purposes, creating reporting issues where incidents can be misfiled or overlooked within safety databases.
7. Critical Need for Transparency
• The lack of comprehensive data and cautious analysis renders ACIP's role questionable and undermines public trust.
• Transparency in reporting deaths and adverse events is essential to ensure that public health decisions are grounded in complete and factual information.
The ACIP meeting raised serious concerns about the way safety data was presented and analyzed, leading to significant decisions regarding the recommendation for a new antibody product. Transparency issues regarding adverse events, especially concerning mortality and seizure risk, highlight the need for a more robust and independent review process to protect public health, particularly for vulnerable populations like newborns.
No comments:
Post a Comment